Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Combination With YL201 With or Without Durvalumab in Extensive Stage Small Cell Lung Cancer
NCT06898957Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2025
- Primary completion
- Jun 2031
- Modality
- Small Molecules, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 10
01
Overview
Phase 1, open-label trial of tarlatamab and YL201 in small cell lung cancer (SCLC) (3 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities and Treatment-emergent Adverse Events up to 3.5 Years. Started May 2025; status: active, not recruiting.
02
Drugs
tarlatamabYL201
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06898957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898957.